Cargando…
Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial
BACKGROUND: We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET). METHODS: ExteN...
Autores principales: | Mortimer, Joanne, Di Palma, Jack, Schmid, Kendra, Ye, Yining, Jahanzeb, Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391844/ https://www.ncbi.nlm.nih.gov/pubmed/30813966 http://dx.doi.org/10.1186/s13058-019-1112-5 |
Ejemplares similares
-
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
por: Chia, Stephen K. L., et al.
Publicado: (2019) -
Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
por: Kruse, Megan L., et al.
Publicado: (2021) -
Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats
por: Secombe, Kate R., et al.
Publicado: (2022) -
Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023) -
Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)